Zhongchao Inc. Reports Fiscal Year 2019 Financial Results

SHANGHAI, May 8, 2020 /PRNewswire/-- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), an online provider of healthcare information, professional training and educational services to healthcare professionals and the public in China, announced today its financial results for the fiscal year ended December 31, 2019.

Fiscal Year 2019 Financial Highlights

• Revenues increased by 15.7% to $14.88 million for fiscal year 2019, primarily driven by increased orders from existing NFP customers including contribution from patient-aid projects that we launched during fiscal year 2019.  
• Gross profit increased by 21.6% to $10.23 million while gross margin improved by 3.3 percentage points to 68.7% for fiscal year 2019.
• Operating income increased by 11.2%, to $3.64 million for fiscal year 2019, primarily attributable to increased gross profit and partially offset by increased operating expenses.
• Net income attributable to the Company's shareholders increased by 34.0% to $4.05 million for fiscal year 2019, primarily driven by increased gross profit and government grants and partially offset by increased operating expenses.
• Earnings per share increased by 26.7% to $0.19 for fiscal year 2019 from $0.15 for fiscal year 2018.

"We are pleased with the strong financial performance for the fiscal year 2019. Our revenues and earnings per share for 2019 as compared to those for 2018 have increased by 15.7% and 26.7%, respectively. Our 2019 financial results highlight continuing strength in our business as one of the leading online providers of healthcare information, professional training and educational services to healthcare professionals and the public in China," said Mr. James Yang, Chairman and Chief Executive Officer of Zhongchao.

"Our platforms of MDMOOC and Sunshine Health Forums continue to expand, gathering increasing number of subscriptions and click-throughs. This, combined with the continuing shift of the healthcare information, education and training services industry from offline to online, particularly against the backdrop of the COVID-19 pandemic, as well as increasing publicity and strengthened financial condition following our recent Nasdaq listing and Initial Public Offering (the "IPO"), bodes well for us," concluded Mr. Yang.

Fiscal Year 2019 Financial Results

Revenues

For the fiscal year ended December 31, 2019, revenues increased by $2.02 million, or 15.7%, to $14.88 million, as compared to $12.87 million for fiscal year 2018. The increase in revenues was primarily driven by increased orders from existing NFP customers including contribution from patient-aid projects that we launched in the end of 2018.  

We generate revenues from pharmaceutical enterprise customers and not-for-profit organizations ("NFPs") customers from design and production of online medical courses, organizing offline medical training services, and other consulting and academic support services.

Cost of revenues

Cost of revenue increased by $0.20 million, or 4.5%, to $4.66 million for fiscal year 2019 as compared to $4.46 million for fiscal year 2018. The increase of cost of revenues was in line with increased revenues. Cost of revenues was comprised of direct related costs incurred by both online and offline seminars and patient-aid projects, including expenses of travelling and accommodation, seminar site-rental, video production and backdrop production, professional service fees charged by experts, salary and welfare expenses incurred by the key members of the editorial, design and production team, and labor cost for patient-aid projects. 

Gross profit

Gross profit increased by $1.82 million, or 21.6%, to $10.23 million for fiscal year 2019 as compared to $8.41 million for fiscal year 2018. The increase in gross profit was attributable to increased revenues as well as improvement in gross margin.

Gross margin increased by 3.3 percentage points to 68.7% for fiscal year 2019 as compared to 65.4% for fiscal year 2018.  The increase in gross margin was related to patient-aid projects that typically incur lower costs than other medical training and education programs.  

Operating expenses

Selling and marketing expenses increased by $0.94 million, or 41.4%, to $3.20 million for fiscal year 2019 as compared to $2.26 million for fiscal year 2018. The increase in selling and marketing expenses was mainly attributable to an increase of $0.68 million in advertising expenses as a result of promoting the Company's Sunshine Health Forums platform and an increase of $0.20 million in payroll and welfare expenses. As a percentage of total revenues, selling and marketing expenses accounted for 21.5% for fiscal year 2019, as compared to 17.6% for fiscal year 2018.

General and administrative expenses increased by $1.09 million, or 77.0%, to $2.52 million for fiscal year 2019 as compared to $1.43 million for fiscal year 2018. The increase in general and administrative expenses was mainly attributable to increase in payroll and welfare expenses as well as professional fees associated with our IPO. General and administrative expenses accounted for 17.0% of the total revenues for fiscal year 2019 as compared to 11.1% for fiscal year 2018.

Research and development expenses decreased by $0.59 million, or 40.3%, to $0.86 million for fiscal year 2019 as compared to $1.45 million for fiscal year 2018. The decrease in research and development expenses was mainly attributable to decreased R&D related payroll and welfare expenses as well as software and related intellectual property expenses. As a percentage of total revenues, research and development expenses accounted 5.8% of the total revenues for fiscal year 2019, as compared to 11.3% for fiscal year 2018.

Total operating expenses increased by $1.45 million, or 28.2%, to $6.58 million for fiscal year 2019 as compared to$5.13 million for fiscal year 2018. The increase in operating expenses was mainly attributable to increased selling and marketing expenses, and general and administrative expenses, and partially offset by the decreased research and development expenses.

Operating income

Income from operations increased by $0.37 million, or 11.2%, to $3.64 million for fiscal year 2019 as compared to $3.27 million for fiscal year 2018. The increase in income from operations was primarily attributable to increased gross profit and decreased research and development expenses and partially offset by increased selling and marketing expenses, and general and administrative expenses.

Operating margin decreased by 1.0 percentage point to 24.5% for fiscal year 2019 from 25.5% for fiscal year 2018.

Interest and other income, net

Interest income increased by $0.02 million, or 10.4%, to $0.21 million for fiscal year 2019 as compared to $0.19 million for fiscal year 2018.

Other income, primarily consisted of government subsidies, netting off against donations made to NFPs, was $0.53 million for fiscal year 2019, compared to $0.04 million for fiscal year 2018. The Company recognized government grants of $0.51 million for development of medical database and online medical lectures sharing application and cloud system in fiscal year 2019.

Income before income taxes

Income before income taxes increased by $0.89 million, or 25.2%, to $4.39 million for fiscal year 2019 as compared $3.50 million for fiscal year 2018. The increase in income before income taxes was primarily attributable to increased operating income and government grants recognized in fiscal year 2019.

Income tax expenses decreased by $0.11 million, or 22.9%, to $0.39 million for fiscal year 2019 as compared $0.50 million for fiscal year 2018. The decrease in income tax expenses was primarily attributable to increased deferred tax benefit from non-deductible advertising expenses which was partially offset by increase in income tax expenses due to increased taxable income for fiscal year 2019.

Net income and EPS

Net income increased by $1.00 million, or 33.3%, to $4.00 million for fiscal year 2019 as compared to $3.00 million for fiscal year 2018. The increase in net income was primarily driven by increased gross profit and government grants and partially offset by increased operating expenses.

Net margin increased by 3.6 percentage points to 26.9% for fiscal year 2019 as compared 23.3% for fiscal year 2018.

After deducting for net loss attributable to non-controlling interests, net income attributable to the Company's shareholders increased by $1.03 million, or 34.0%, to $4.05 million for fiscal year 2019 as compared to $3.02 million for fiscal year 2018.

Earnings per share increased by $0.04, or 26.7%, to $0.19 for fiscal year 2019 as compared to $0.15 for fiscal year 2018.

Financial Condition

As of December 31, 2019, the Company had cash, cash equivalents and short-term investments of $7.83 million, compared to $9.08 million as of December 31, 2018. Accounts receivable were $5.08 million as of December 31, 2019, compared to $1.99 million as of December 31, 2018. Short-term borrowings were $nil and $0.73 million, as of December 31, 2019 and 2018, respectively. Working capital was $12.15 million as of December 31, 2019, compared to $10.23 million as of December 31, 2018.

Net cash provided by operating activities was $1.41 million for fiscal year 2019, compared to $1.31 million for fiscal year 2018. Net cash used in investing activities was $0.20 million for fiscal year 2019, compared to $0.50 million for fiscal year 2018. Net cash used in financing activities was $1.19 million for fiscal year 2019, compared to net cash provided by financing activities of $4.34 million for fiscal year 2018. 

Recent Developments

On April 24, 2020, the Company announced the launch of virtual seminar series (the "Virtual Seminar Series") aiming to connect global healthcare professionals through knowledge and experience sharing in their fight against the COVID-19 ("coronavirus") pandemic. The Virtual Seminar Series was jointly hosted by the Beijing Medical and Health Foundation. The first panel session on neonatology was held on April 24, 2020 and jointly moderated by Dr. Lizhong Du, a renowned neonatologist and professor at Zhejiang University of China, and Dr. Anna Lavizzari, professor of Neonatal and Perinatology at University of Milan of Italy, with panelists from 7 countries including Brazil, China, Italy, Norway, Poland, Spain and Turkey.

On April 1, 2020, the Company announced that Sunshine Health Forums, the Company's online portal providing healthcare and wellness knowledge to the general public, hit a major milestone with accumulative subscribers  and click-throughs (since its launch in mid-2016) exceeding 5.1 million and 1.3 billion, respectively, by the end of March.

On March 23, 2020, the Company provided an update regarding the impact of COVID-19 on its operations and announced it has successfully developed and launched coronavirus curriculum with over 60 courses covering a wide range of medical specialties including anesthesiology, surgery, oncology, obstetrics and gynecology, pediatrics, infectious disease, respirology, critical medicine and psychiatry. The Curriculum includes both free online courses developed independently by the Company and customized courses developed through partnership/sponsorship with leading pharmaceutical companies and not-for-profit organizations, including Sanofi Pasteur, Fresenius Kabi, Johnson & Johnson, Lundbeck, Boehringer Ingelheim, Chinese Journal of Anesthesiology, Chinese Journal of Surgery, obgy.cn, China Association of Health Promotion and Education, and the Chinese Society of Psychiatry.

On March 2, 2020, the Company announced that Network 1 Financial Securities, Inc., who acted as the lead underwriter and bookrunner of the Company's IPO, had partially exercised their over-allotment option and purchased an additional 315,003 Class A ordinary shares at the IPO price of $4.00 per share. As a result, the Company raised gross proceeds of approximately $1.26 million, in addition to the previously announced IPO gross proceeds of $12.0 million, or combined gross proceeds in this IPO of approximately $13.26 million, before underwriting discounts and commissions and offering expenses.

On February 21, 2020, the Company announced the pricing of its IPO of 3,000,000 Class A ordinary shares at a public offering price of $4.00 per share, generating gross proceeds of approximately $12.0 million, and net proceeds of approximately $9.97 million. The shares began trading on the NASDAQ Capital Market on February 24, 2020, under the ticker symbol "ZCMD". The offering was closed on February 26, 2020.

About Zhongchao Inc.

Incorporated in 2012 with headquarter offices in Shanghai and Beijing, China, Zhongchao Inc. is an online provider of healthcare information, professional training and educational services to healthcare professionals under its "MDMOOC" platform (www.mdmooc.org) and to the public under its "Sunshine Health Forums" platform (www.ygjkclass.com) in China. More information about the Company can be found at its investor relations website at http://izcmd.com.

Safe Harbor Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following:  the Company's goals and strategies; the Company's future business development; product and service demand and acceptance; changes in technology; economic conditions; the growth of the professional training and educational services market in China and the other international markets the Company plans to serve; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in China and the international markets the Company plans to serve and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC, the length and severity of the recent coronavirus outbreak, including its impacts across our business and operations.  For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward‐looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

At the Company:
Pei Xu, CFO
Email: [email protected]
Phone: +86 21-3220-5987

Investor Relations:
Tony Tian, CFA        
Weitian Group LLC
Email: [email protected]
Phone: +1 732-910-9692

SOURCE Zhongchao Inc.